Login Register Cart 0
Recent Advances in Inflammation & Allergy Drug Discovery

Recent Advances in Inflammation & Allergy Drug Discovery

Editor-in-Chief

ISSN (Print): 2772-2708
ISSN (Online): 2772-2716

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Editorial

Detection of Inflammatory Bowel Disease Activity by Non-invasive Biomarkers: Still a Long Way Ahead

Author(s): Stefano Fiorucci* and Ginevra Urbani

Volume 19, Issue 3, 2025

Published on: 02 May, 2025

Page: [275 - 278] Pages: 4

DOI: 10.2174/0127722708402763250424092507

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor
Next »
[1]
Tavakoli P, Vollmer-Conna U, Hadzi-Pavlovic D, Grimm MC. A review of inflammatory bowel disease: A model of microbial, immune and neuropsychological integration. Public Health Rev 2021; 42: 1603990.
[http://dx.doi.org/10.3389/phrs.2021.1603990] [PMID: 34692176]
[2]
Caron B, Honap S, Peyrin-Biroulet L. Epidemiology of inflammatory bowel disease across the ages in the era of advanced therapies. J Crohn’s Colitis 2024; 18 (Suppl. 2): ii3-ii15.
[http://dx.doi.org/10.1093/ecco-jcc/jjae082] [PMID: 39475082]
[3]
Odze RD. A contemporary and critical appraisal of ‘indeterminate colitis’. Mod Pathol 2015; 28 (Suppl. 1): S30-46.
[http://dx.doi.org/10.1038/modpathol.2014.131] [PMID: 25560598]
[4]
Rutkowski K, Udrycka K, Włodarczyk B, Małecka-Wojciesko E. Microscopic colitis: An underestimated disease of growing importance. J Clin Med 2024; 13(19): 5683.
[http://dx.doi.org/10.3390/jcm13195683] [PMID: 39407743]
[5]
Piovani D, Danese S, Peyrin-Biroulet L, Nikolopoulos GK, Lytras T, Bonovas S. Environmental risk factors for inflammatory bowel diseases: An umbrella review of meta-analyses. Gastroenterology 2019; 157(3): 647-659.e4.
[http://dx.doi.org/10.1053/j.gastro.2019.04.016] [PMID: 31014995]
[6]
Torres J, Gomes C, Jensen CB, et al. Risk factors for developing inflammatory bowel disease within and across families with a family history of IBD. J Crohn’s Colitis 2023; 17(1): 30-6.
[http://dx.doi.org/10.1093/ecco-jcc/jjac111] [PMID: 35943898]
[7]
Bretto E, Frara S, Armandi A, et al. Helicobacter pylori in inflammatory bowel diseases: Active protagonist or innocent bystander? Antibiotics 2024; 13(3): 267.
[http://dx.doi.org/10.3390/antibiotics13030267] [PMID: 38534702]
[8]
McDowell C, Farooq U, Haseeb M. Inflammatory bowel disease. StatPearls 2023.
[9]
Ranasinghe IR, Tian C, Hsu R. Crohn Disease. Treasure Island, FL: StatPearls 2025.
[10]
Lynch WD, Hsu R. Ulcerative Colitis. Treasure Island, FL: StatPearls 2025.
[11]
Hunter Gibble T, Sweeney C, Wolin D, et al. Evaluation of the symptoms and clinical characteristics of crohn’s disease and ulcerative colitis that affect healthcare providers’ treatment choices. Crohns Colitis 360 2024; 6(4): otae053.
[http://dx.doi.org/10.1093/crocol/otae053] [PMID: 39403225]
[12]
Liu D, Saikam V, Skrada KA, Merlin D, Iyer SS. Inflammatory bowel disease biomarkers. Med Res Rev 2022; 42(5): 1856-87.
[http://dx.doi.org/10.1002/med.21893] [PMID: 35603998]
[13]
Vrabie R, Kane S. Noninvasive markers of disease activity in inflammatory bowel disease. Gastroenterol Hepatol 2014; 10(9): 576-84.
[PMID: 27551251]
[14]
Honap S, Jairath V, Danese S, Peyrin-Biroulet L. Navigating the complexities of drug development for inflammatory bowel disease. Nat Rev Drug Discov 2024; 23(7): 546-62.
[http://dx.doi.org/10.1038/s41573-024-00953-0] [PMID: 38778181]
[15]
Fiorucci S, Marchianò S, Urbani G, et al. Immunology of bile acids regulated receptors. Prog Lipid Res 2024; 95: 101291.
[http://dx.doi.org/10.1016/j.plipres.2024.101291] [PMID: 39122016]
[16]
Biagioli M, Marchianò S, Carino A, et al. Bile acids activated receptors in inflammatory bowel disease. Cells 2021; 10(6): 1281.
[http://dx.doi.org/10.3390/cells10061281] [PMID: 34064187]
[17]
Danese S, Panés J. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. Gastroenterology 2014; 147(5): 981-9.
[http://dx.doi.org/10.1053/j.gastro.2014.08.044] [PMID: 25220794]
[18]
Mencarelli A, Cipriani S, Francisci D, et al. Highly specific blockade of CCR5 inhibits leukocyte trafficking and reduces mucosal inflammation in murine colitis. Sci Rep 2016; 6(1): 30802.
[http://dx.doi.org/10.1038/srep30802] [PMID: 27492684]
[19]
Biagioli M, Di Giorgio C, Morretta E, et al. Development of dual GPBAR1 agonist and RORγt inverse agonist for the treatment of inflammatory bowel diseases. Pharmacol Res 2024; 208: 107403.
[http://dx.doi.org/10.1016/j.phrs.2024.107403] [PMID: 39265668]
[20]
Mohanty I, Allaband C, Mannochio-Russo H, et al. The changing metabolic landscape of bile acids – keys to metabolism and immune regulation. Nat Rev Gastroenterol Hepatol 2024; 21(7): 493-516.
[http://dx.doi.org/10.1038/s41575-024-00914-3] [PMID: 38575682]
[21]
Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe 2014; 15(3): 382-92.
[http://dx.doi.org/10.1016/j.chom.2014.02.005] [PMID: 24629344]
[22]
Iacucci M, Santacroce G, Maeda Y, Ghosh S. AI-driven personalized medicine: Transforming clinical practice in inflammatory bowel disease. Gastroenterology 2025; 5085(25): 00494-9.
[http://dx.doi.org/10.1053/j.gastro.2025.03.005] [PMID: 40074186]

Rights & Permissions Print Cite
Article Metrics
Pdf icon 27
Html icon 2
Find your institution